Jose Lopez-Ribot

Dr. Jose Lopez-Ribot

Department of Biology, South Texas Center for Emerging Infections Diseases, The University of Texas at San Antonio, San Antonio, TX 78249, USA
orcid

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2001 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
GRGordon Ramage
Gordon Ramage
KWKacy Vande Walle
Kacy Vande Walle
Brian WickesBrian Wickes
Brian Wickes
Jose Lopez-RibotJose Lopez-Ribot
Jose Lopez-Ribot
Candida albicans is implicated in many biomaterial-related infections. Typically, these infections are associated with biofilm formation. Cells in biofilms display phenotypic traits that are dramatically different from those of their free-floating planktonic counterparts and are notoriously resistant to antimicrobial agents. Consequently, biofilm-related infections are inherently difficult to treat and to fully eradicate with normal treatment regimens. Here, we report a rapid and highly reproducible microtiter-based colorimetric assay for the susceptibility testing of fungal biofilms, based on the measurement of metabolic activities of the sessile cells by using a formazan salt reduction assay. The assay was used for in vitro antifungal susceptibility testing of several C. albicans strains grown as biofilms against amphotericin B and fluconazole and the increased resistance of C. albicans biofilms against these antifungal agents was demonstrated. Because of its simplicity, compatibility with a widely available 96-well microplate platform, high throughput, and automation potential, we believe this assay represents a promising tool for the standardization of in vitro antifungal susceptibility testing of fungal biofilms.

1 November 2002 in Applied and Environmental Microbiology
Verified
Journal Article
Open access
PDF file
GRGordon Ramage
Gordon Ramage
SSStephen P. Saville
Stephen P. Saville
Brian WickesBrian Wickes
Brian Wickes
Jose Lopez-RibotJose Lopez-Ribot
Jose Lopez-Ribot
Farnesol is a quorum-sensing molecule that inhibits filamentation in Candida albicans . Both filamentation and quorum sensing are deemed to be important factors in C. albicans biofilm development. Here we examined the effect of farnesol on C. albicans biofilm formation. C. albicans adherent cell populations (after 0, 1, 2, and 4 h of adherence) and preformed biofilms (24 h) were treated with various concentrations of farnesol (0, 3, 30, and 300 μM) and incubated at 37°C for 24 h. The extent and characteristics of biofilm formation were then assessed microscopically and with a semiquantitative colorimetric technique based on the use of 2,3-bis(2-methoxy-4-nitro-5-sulfo-phenyl)-2H-tetrazolium-5-carboxanilide. The results indicated that the effect of farnesol was dependent on the concentration of this compound and the initial adherence time, and preincubation with 300 μM farnesol completely inhibited biofilm formation. Supernatant media recovered from mature biofilms inhibited the ability of planktonic C. albicans to form filaments, indicating that a morphogenetic autoregulatory compound is produced in situ in biofilms. Northern blot analysis of RNA extracted from cells in biofilms indicated that the levels of expression of HWP1 , encoding a hypha-specific wall protein, were decreased in farnesol-treated biofilms compared to the levels in controls. Our results indicate that farnesol acts as a naturally occurring quorum-sensing molecule which inhibits biofilm formation, and we discuss its potential for further development and use as a novel therapeutic agent.

1 April 2005 in Eukaryotic Cell
Verified
Journal Article
Open access
PDF file
GRGordon Ramage
Gordon Ramage
SSStephen P. Saville
Stephen P. Saville
DTDerek P. Thomas
Derek P. Thomas
Jose Lopez-RibotJose Lopez-Ribot
Jose Lopez-Ribot

1 October 2003 in Eukaryotic Cell
Verified
Journal Article
Closed access
PDF file
SSStephen P. Saville
Stephen P. Saville
ALAnna L. Lazzell
Anna L. Lazzell
CMCarlos Monteagudo
Carlos Monteagudo
Jose Lopez-RibotJose Lopez-Ribot
Jose Lopez-Ribot
It is widely assumed that the ability of Candida albicans to switch between different morphologies is required for pathogenesis. However, most virulence studies have used mutants that are permanently locked into either the yeast or filamentous forms which are avirulent but unsuitable for discerning the role of morphogenetic conversions at the various stages of the infectious process. We have constructed a strain in which this developmental transition can be externally modulated both in vitro and in vivo. This was achieved by placing one copy of the NRG1 gene (a negative regulator of filamentation) under the control of a tetracycline-regulatable promoter. This modified strain was then tested in an animal model of hematogenously disseminated candidiasis. Mice injected with this strain under conditions permitting hyphal development succumbed to the infection, whereas all of the animals injected under conditions that inhibited this transition survived. Importantly, fungal burdens were almost identical in both sets of animals, indicating that, whereas filament formation appears to be required for the mortality resulting from a deep-seated infection, yeast cells play an important role early in the infectious process by extravasating and disseminating to the target organs. Moreover, these infecting Candida yeast cells still retained their pathogenic potential, as demonstrated by allowing this developmental transition to occur at various time points postinfection. We demonstrate here the importance of morphogenetic conversions in C. albicans pathogenesis. This engineered strain should provide a useful tool in unraveling the individual contributions of the yeast and filamentous forms at various stages of the infectious process.

1 November 2006 in FEMS Yeast Research
Verified
Journal Article
Closed access
PDF file
GRGordon Ramage
Gordon Ramage
JMJosã© Pedro Martã­nEz
Josã© Pedro Martã­nEz
Jose Lopez-RibotJose Lopez-Ribot
Jose Lopez-Ribot

1 August 2008 in Nature Protocols
Verified
Journal Article
Closed access
PDF file
CPChristopher G Pierce
Christopher G Pierce
PUPriya Uppuluri
Priya Uppuluri
ATAmanda R Tristan
Amanda R Tristan
FWFloyd L Wormley
Floyd L Wormley
EMEilidh Mowat
Eilidh Mowat
Jose Lopez-RibotJose Lopez-Ribot
Jose Lopez-Ribot